Economic Burden of Respiratory Syncytial Virus Infection in Colombia: A Nationwide Cost-of-Illness Study
Journal of Health Economics and Outcomes Research · 19.12.2025 · 12 (2)
DOI: 10.36469/001c.151678 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Health Economics and Outcomes Research, online erschienen am 19.12.2025. Verfasst von Giancarlo Buitrago und 7 weiteren Autor:innen. Beteiligte Einrichtung: Universidad Nacional de Colombia, Bogotá, Colombia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Respiratory syncytial virus (RSV) is one of the leading causes of acute respiratory infections and severe cases can lead to hospitalization or death. The epidemiology and health resource utilization of RSV infection in Colombia is not well understood. Given the recent availability of new RSV preventatives, this study estimated the economic burden of RSV in Colombia.
Methods
This cost-of-illness study employed a retrospective cohort design and bottom-up costing approach to estimate direct healthcare costs associated with RSV-related acute respiratory infections across pediatric and adult populations. Administrative data from sentinel surveillance centers belonging to the National Epidemiological Surveillance System of the Colombian National Institute of Health, the database for the study of the Capitation Payment Unit database, and the Integrated Social Protection Information System were utilized to estimate RSV incidence, mortality, and healthcare costs. Costs were expressed in US dollars.
Results
A total of 264 744 RSV-related healthcare consultations were identified in 2019. The highest incidence was among infants under 1 year (61.8 per 1000), while general mortality was highest in adults 75 years and older (46.6 per 100,000), followed by infants (42.4 per 100 000). Total direct healthcare costs were estimated at $682.87 million (95% CI, $281.39 million–$1084.35 million), with the largest share contributed by individuals aged 15 years and older. Among infants under 1 year, intensive care unit (ICU) patients had the highest average cost ($3619), and hospitalization accounted for 49% of total spending, followed by ICU services (29%) and medications (8%).
Conclusions
RSV poses a significant economic burden on Colombia’s healthcare system. These findings support the need for targeted prevention strategies and efficient resource allocation. Future research should incorporate indirect costs and long-term impacts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Universidad Nacional de Colombia, Bogotá, Colombia.
- Fundación Cardioinfantil - Instituto de Cardiología, Bogotá, Colombia.
- Hospital Universitario Nacional de Colombia, Bogotá, Colombia.
- Pfizer SAS, Bogotá, Colombia.
ORCID-Profile: Giancarlo Buitrago
Zitieren
APA
Buitrago, G., González-Caicedo, P., Reyes-Sanchez, J. M., Burgos, C., Arciniegas, J., La Rotta, J., Escobar, O., & Alamo, A. (2025). Economic Burden of Respiratory Syncytial Virus Infection in Colombia: A Nationwide Cost-of-Illness Study. Journal of Health Economics and Outcomes Research, 12(2). https://doi.org/10.36469/001c.151678
Vancouver
Buitrago G, González-Caicedo P, Reyes-Sanchez JM, Burgos C, Arciniegas J, La Rotta J, et al. Economic Burden of Respiratory Syncytial Virus Infection in Colombia: A Nationwide Cost-of-Illness Study. Journal of Health Economics and Outcomes Research. 2025;12(2). doi:10.36469/001c.151678
BibTeX
@article{Buitrago2025,
author = {Buitrago, Giancarlo and González-Caicedo, Paula and Reyes-Sanchez, Juan M and Burgos, Claudia and Arciniegas, Jair and La Rotta, Jorge and Escobar, Omar and Alamo, Andreina},
title = {Economic Burden of Respiratory Syncytial Virus Infection in Colombia: A Nationwide Cost-of-Illness Study},
journal = {Journal of Health Economics and Outcomes Research},
year = {2025},
volume = {12},
number = {2},
doi = {10.36469/001c.151678}
}
EUVIMED